BzATP triethylammonium salt 是一种P2X受体激动剂，对 P2X1，P2X2，P2X3，P2X2/3，P2X4 和 P2X7 的pEC50分别为 8.74，5.26，7.10，7.50， 6.19，6.31 和 5.33。BzATP triethylammonium salt 对 P2X7 受体有效，对大鼠 P2X7 和小鼠 P2X7 的EC50分别为 3.6 μM 和 285 μM。
| 生物活性 | BzATP triethylammonium salt acts as aP2X receptoragonist withpEC50s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively[1]. BzATP triethylammonium salt is potent at P2X7 receptors withEC50s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively[2]. |
| IC50& Target | pEC50: 8.74 (P2X1), 5.26 (P2X2), 7.10 (P2X3), 6.19 (P2X2/3), 6.31 (P2X4), 5.33 (P2X7)[1]
EC50 3.6 μM (rat P2X7); 285 μM (mouse P2X7)[2] |
体外研究
(In Vitro) | BzATP (10-1000 μM; 24 h) promotes the proliferation and migration of U87 and U251 glioma cells[3].
P2X7R protein expression is induced by BzATP (100 μM; 6-48 h) in human glioma cells[3].
Cell Proliferation Assay[3] | Cell Line: | U87 and U251 glioma cells | | Concentration: | 5, 10, 50, 100, 500 and 1000 μM | | Incubation Time: | 2, 6, 12, 24, 48 and 72 hours | | Result: | The proliferation of U87 and U251 glioma cell lines was significantly increased in the presence of 10-1000 uM and 100-1000 μM, respectively.
The peak of cell proliferation of both U87 and U251 cell lines was at 100 μM.
The optimal incubation time is 24 hours in both U87 and U251 cells lines. |
Western Blot Analysis[3] | Cell Line: | U87 and U251 glioma cells | | Concentration: | 100 μM | | Incubation Time: | 6-48 hours | | Result: | Induced the upregulation of P2X7R. |
|
体内研究
(In Vivo) | BzATP (5 mg/kg) significantly promotes P2X7R expression in the intestines compared with intestines in the sham group and the control group after cecal ligation and puncture (CLP) induction[4].
| Animal Model: | Male 2-month-old C57BL/6 mice (each weighing between 20 and 25 g)[4] | | Dosage: | 5 mg/kg | | Administration: | Injected through the intraperitoneal route | | Result: | At 48 hours, mice in the treated group and control group exhibited mortalities of 91% and 86%, respectively. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | -20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| 溶解性数据 | In Vitro: H2O : 50 mg/mL(49.07 mM;Need ultrasonic) 配制储备液 | 1 mM | 0.9814 mL | 4.9069 mL | 9.8138 mL | | 5 mM | 0.1963 mL | 0.9814 mL | 1.9628 mL | | 10 mM | 0.0981 mL | 0.4907 mL | 0.9814 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： PBS Solubility: 100 mg/mL (98.14 mM); Clear solution; Need ultrasonic
*以上所有助溶剂都可在本网站选购。 |
